NGL Fine-Chem (NSE:NGLFINE) Equity-to-Asset: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:NGLFINE NGL Fine-Chem Ltd NSE:NGLFINE
80 GF Score
Price ₹2,731.60
GF Value ₹3,086.95
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is NGL Fine-Chem Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. NGL Fine-Chem's Total Stockholders Equity for the quarter that ended in Jun. 2026 was ₹ Mil. NGL Fine-Chem's Total Assets for the quarter that ended in Jun. 2026 was ₹ Mil.

The historical rank and industry rank for NGL Fine-Chem's Equity-to-Asset or its related term are showing as below:

NSE:NGLFINE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.56   Med: 0.65   Max: 0.78
Current: 0.6

During the past 13 years, the highest Equity to Asset Ratio of NGL Fine-Chem was 0.78. The lowest was 0.56. And the median was 0.65.

NSE:NGLFINE's Equity-to-Asset is ranked better than
50.25% of 1007 companies
in the Drug Manufacturers industry
Industry Median: 0.6 vs NSE:NGLFINE: 0.60

NGL Fine-Chem  (NSE:NGLFINE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


NGL Fine-Chem Equity-to-Asset Related Terms


NGL Fine-Chem Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for NGL Fine-Chem's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NGL Fine-Chem Equity-to-Asset Chart

NGL Fine-Chem Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 0.78 0.74 0.65 0.60

NGL Fine-Chem Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.62 - 0.60 -

NSE:NGLFINE vs LLY, JNJ, ABBV: Equity-to-Asset Comparison

For the Drug Manufacturers - General subindustry, NGL Fine-Chem's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NGL Fine-Chem Equity-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where NGL Fine-Chem's Equity-to-Asset falls into.


NSE:NGLFINE
80GF Score
NGL Fine-Chem Ltd NSE:NGLFINE
Equity-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NGL Fine-Chem Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

NGL Fine-Chem's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

Equity to Asset (A: Mar. 2026 )=Total Stockholders Equity/Total Assets
=3292.379/5454.958
=0.60

NGL Fine-Chem's Equity to Asset Ratio for the quarter that ended in Jun. 2026 is calculated as

Equity to Asset (Q: Jun. 2026 )=Total Stockholders Equity/Total Assets
=/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?

Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be undervalued. The current stock price of ₹2,731.60 is trading 11.5% below its estimated GF Value™ of ₹3,086.95. GuruFocus considers NGL Fine-Chem to be Modestly Undervalued.

Key valuation signals for NSE:NGLFINE:

  • Equity-to-Asset:
  • GF Value™: ₹3,086.95 vs. price of ₹2,731.60 (11.5% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NGL Fine-Chem Business Description

Other Exchanges 524774:India
Address 301, E Square, Subhash Road, Vile Parle (East), Mumbai, MH, IND, 400057
NGL Fine-Chem Ltd is an Indian manufacturer of active pharmaceutical ingredients (APIs) and intermediates, operating in a single pharmaceutical segment. The company produces a range of veterinary and human health APIs, including antiparasitics, antibiotics, and anti-inflammatory products, along with advanced intermediates used in pharmaceutical synthesis. Its customers are primarily pharmaceutical and animal health companies, both domestic and multinational, which use its products as inputs for finished dosage formulations. NGL Fine-Chem serves markets across India, Europe, the Asia Pacific, the United States, and other regions, with exports accounting for a significant share of revenue. The company generates revenue through the sale of APIs and intermediates, supported by manufacturing facilities in India that comply with regulatory standards. Its business depends on product quality, regulatory approvals, and long-term relationships with formulation manufacturers.
80GF Score

Get the complete analysis for NSE:NGLFINE

Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,731.60
Price
₹3,086.95
GF Value